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The central ghrelin signaling system engages key pathways of importance for feeding control, recently
shown to include those engaged in anxiety-like behavior in rodents. Here we sought to determine
whether ghrelin impacts on the central serotonin system, which has an important role in anxiety. We
focused on two brain areas, the amygdala (of importance for the mediation of fear and anxiety) and the
dorsal raphe (i.e. the site of origin of major afferent serotonin pathways, including those that project to
the amygdala). In these brain areas, we measured serotonergic turnover (using HPLC) and the mRNA
expression of a number of serotonin-related genes (using real-time PCR). We found that acute central
administration of ghrelin to mice increased the serotonergic turnover in the amygdala. It also increased
the mRNA expression of a number of serotonin receptors, both in the amygdala and in the dorsal raphe.
Studies in ghrelin receptor (GHS-R1A) knock-out mice showed a decreased mRNA expression of sero-
tonergic receptors in both the amygdala and the dorsal raphe, relative to their wild-type littermates. We
conclude that the central serotonin system is a target for ghrelin, providing a candidate neurochemical
substrate of importance for ghrelin’s effects on mood.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
The circulating hormone ghrelin (Kojima et al., 1999) has an
established role in food intake and body fat accumulation (Tschop
et al., 2000). Increasing evidence suggests that the neurobiolog-
ical effects of ghrelin extend beyond energy balance, to include
reward-motivated behavior (Abizaid et al., 2006; Jerlhag et al.,
2009; Egecioglu et al., 2010; Perello et al., 2010; Skibicka et al.,
2012), memory (Diano et al., 2006) and mood (Asakawa et al.,
2001). There are indications that the central ghrelin signaling sys-
tem could also be involved in the regulation of anxiety. Ghrelin hasent of Molecular and Clinical
cademy at the University of
. Tel.: þ46 31 786 6747.
n).
r Ltd.Open access under CC BY-NC-NDbeen shown to increase anxiety-like behavior in rodents when
administered acutely, both peripherally or centrally (Asakawa et al.,
2001; Carlini et al., 2002, 2004), although it has also been reported
to reduce the depressive and anxiogenic effects of acute stress in
mice (Lutter et al., 2008). We have also shown that chronic central
ghrelin administration increases both anxiety- and depression-like
behavior in rats (Hansson et al., 2011). Consistent with this,
administration of antisense for ghrelin decreases anxiety-like
behavior in rats (Kanehisa et al., 2006) and gastrectomy surgery,
that substantially reduces circulating ghrelin levels, was associated
with a decrease in anxiety- and depression-like behavior in rats
(Salome et al., 2011). We have also shown that panic disorder is
associated with a polymorphism in the preproghrelin gene in
humans (Hansson et al., 2013), further enhancing the connection
between ghrelin and anxiety-related disorders.
One potential candidate target system for these neurobiological
effects of ghrelin on anxiety-like behavior is the central serotonergic
system. Destruction of serotonergic neurons as well as depleting the
brain of serotonin (5-HT) decreases anxiety-like behavior
(Soderpalm and Engel, 1990), and activation of the 5-HT1A license.
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olytic effect (Akimova et al., 2009), while increased serotonergic
signaling increases anxiety (Graeff et al., 1996). There are several
studies proposing an interaction between ghrelin and the seroto-
nergic system. Ghrelin has been shown to decrease serotonergic
release from hypothalamic synaptosomes (Brunetti et al., 2002) as
well as from hippocampal slices (Ghersi et al., 2011). Administration
of serotonin or a serotonin receptor agonist into the hypothalamus
decreases ghrelin-induced food intake as well as ghrelin-induced
increases in respiratory quotient (Currie et al., 2010). In addition,
ghrelin-induced increases in food intake and memory retention are
attenuated by administration of the selective serotonin reuptake
inhibitor (SSRI) ﬂuoxetine (Carlini et al., 2007). Other effects of
ghrelin that have also been suggested to be mediated via a seroto-
nergic pathway include activationof theHPA-axis, regulationof body
temperature and the secretion of growth hormone (Pinilla et al.,
2003; Jaszberenyi et al., 2006). Serotonergic cell bodies located in
the dorsal and medial raphe nuclei send serotonergic projections to
the forebrain, including the limbic midbrain area (Dahlstroem and
Fuxe, 1964). We have recently shown that ghrelin alters the ﬁring
rate of cells in the dorsal raphe in vitro (Hansson et al., 2011).
In a recent study,we identiﬁed the amygdala as a target for ghrelin,
involving neuroanatomical, electrophysiological and behavioral
studies. We also showed that intra-amygdala ghrelin administration
affects feeding as well as anxiety-like behavior (Alvarez-Crespo et al.,
2012). The amygdala is an important brain region for the regulation of
fear and anxiety (Davis, 1992). There are indications that the seroto-
nergic system is involved inmediating fear and anxiety in this region;
blockade of serotonergic receptors in the amygdala is anxiolytic,while
intra-amygdaloid injection of a serotonin receptor agonist has the
opposite effect (Costall et al., 1989). It is not yet known whether
ghrelin’s effects onanxiety-likebehavior in rodents involves increased
serotonin signaling in the amygdala, forming a key aim of our study.
In the present study, we sought to explore the impact of: I) acute
central ghrelin administration and II) knock-out of the ghrelin re-
ceptor, GHS-R1A, on serotonergic turnover and the mRNA expres-
sion of serotonergic receptors, enzymes and transporters in
relevant brain areas.
2. Materials and methods
2.1. Animals
For the acute ghrelin treatment, male C57/Bl6J mice (8e10 weeks, Taconic,
Denmark) were used. Upon arrival in the animal facility theywere group housed and
allowed to acclimatise for one week before the experiment. After surgery, they were
housed individually. Male GHS-R1A knock-out mice (9e11 weeks) and their wild-
type littermates were also used in the study. The derivation of these mice has
been described previously (Egecioglu et al., 2010). All animals were kept under a
12:12 LD cycle (lights on at 0700) with free access to standard food pellets and tap
water. The studies were approved by the local Ethics Committee at the University of
Gothenburg, Sweden.
2.2. Surgical procedure for central ghrelin administration
For intracerebroventricular (i.c.v.) catheter placement, mice were anaesthetized
using isoﬂurane (induction4%,maintenance 3e4%;airﬂow, 260ml/min) andplaced in
a stereotactic frame (Kopf Instruments, Tujunga, CA,USA). A steel guide cannula (AG-8,
code 806302 from Agntho’s, Lidingö, Sweden) was implanted into the third dorsal
ventricle using the following coordinates from bregma: AP0.9 mm, ML 0.0 mm, DV
1.0mm(Paxinos and Franklin, 2001). The cannulawas anchored to the skullwith one
jeweller’s screw (Agntho’s) and dental cement (Dentalon, Agntho’s, ﬂuid 7509, pow-
der 7508) attached to the cannula and to the stabilizing screw. Romefen (5mg/kg)was
given as a postoperative analgesic and saline (0.5 ml per mouse) was given subcuta-
neously to prevent dehydration. After surgery, the mice were allowed to recover for
one week, before any experimental procedures were undertaken.
2.3. Determination of the tissue concentration of serotonin and its metabolite 5-
hydroxyindolacetic acid (5-HIAA)
To explore the impact of acute central ghrelin administration on the tissue
concentration of serotonin and the serotonin metabolite 5-HIAA in the amygdala
and dorsal raphe, dissected tissue was collected from ghrelin- and saline-treatedmice. Thus, mice bearing chronically implanted i.c.v. catheters were injected with
acylated ghrelin (Tocris, Bristol, UK; 1 mg/ml, ﬂow rate 1 mL/min, this dose was based
on (Jerlhag et al., 2006)) or an equal volume (1 mL) vehicle saline solution, using CMA
infusion pumps (CMA Microdialysis AB, Solna, Sweden) and Hamilton syringes
(Genetec, Västra Frölunda, Sweden). Thirty min after the i.c.v. infusion, mice were
anaesthetized using isoﬂurane and decapitated. Brains were rapidly removed and
the amygdala and dorsal raphe nucleus were dissected manually using a brain
matrix, using coordinates and visual landmarks. The coordinates used were (i) for
the amygdala: 0.82 to 2.80 mm anterioreposterior relative to Bregma, 4.5
to 5.8 mm depth and 1.5e3.0 mm lateral to the midline and (ii) for the dorsal
raphe: 4.1 to 5.1 mm anterior-posterior relative to Bregma, 2.6 to 3.5 mm
depth and 0.0  0.8 mm lateral to the midline (Paxinos and Franklin, 2001). All
dissections were performed during daytime and used a balanced design with
respect to the time of injection. Dissected brain areas were frozen on dry ice and
stored in 80 C for later determination of serotonin and 5-HIAA concentration.
We also investigated whether GHS-R1A knock-out mice have altered tissue
concentration of serotonin and 5-HIAA in the amygdala and dorsal raphe. GHS-R1A
knock-out mice and wild-type littermates were anaesthetized using isoﬂurane and
decapitated. Brains were rapidly removed and the amygdala and dorsal raphe nu-
cleus were dissected and stored as described above.
2.3.1. Serotonin and metabolite measurements
To explore the effects of ghrelin on the activity of the serotonergic neurons, we
measured the tissue concentrations of serotonin and its metabolite 5-HIAA after
acute ghrelin treatment and in GHS-R1A knock-out mice in the amygdala and the
dorsal raphe.
Individual brain tissue samples were homogenized (using a Soniﬁer Cell Dis-
ruptor B30; Branson Sonic Power Co. Danbury, CT, USA) in a solution of 0.1 M
perchloric acid, 5.37 mM EDTA and 0.65 mM glutathione. After centrifugation
(14000 rpm, 4 C, 10 min) the supernatant was collected and immediately analyzed
for serotonin and 5-HIAA using a split fraction HPLC-ED system. Serotonin was
analyzed on an ion-exchange column (Nucleosil, 5 m SA 100 A, 150  2 mm, Phe-
nomenex, Torrance, CA, USA) with a mobile phase consisting of 13.3 g citric acid,
5.84 g NaOH, 40 mg EDTA, and 200 ml methanol in distilled water to a total of
1000 ml. 5-HIAAwas analyzed on a reverse phase column (Nucleosil, 3 m, C18, 100 A,
50 2mm, Phenomenex) with amobile phase consisting of 11.22 g citric acid, 3.02 g
dipotassium phosphate, 40mg EDTA, and 60mlmethanol in distilledwater to a total
volume of 1000 ml.
2.4. Gene expression
We explored the impact of acute ghrelin treatment on gene expression of
serotonin-related genes in dissected amygdala and dorsal raphe tissue. All pro-
cedures for infusion, brain removal and dissection were identical to those described
above. For the gene expression however, the mice were anaesthetized and brains
dissected 100 min after the ghrelin infusion. In addition, hypothalami of the saline-
treated mice were dissected for determination of the GHS-R1A expression in order
to assess relative levels of this receptor in different tissues. Dissected brain areas
were frozen on dry ice and kept in RNA later in þ4 C over night. The next day, the
RNA later was removed and the brain tissue samples stored in 20 C for later
determination of mRNA expression.
We also assessed the expression of serotonin-related genes in GHS-R1A knock-
out mice and wild-type littermate mice. The brain areas of these mice were
dissected and stored as described above.
2.4.1. RNA isolation and mRNA expression
Individual brain samples were homogenized in Qiazol (Qiagen, Hilden, Ger-
many) using a TissueLyzer (Qiagen). Total RNA was extracted using RNeasy Lipid
Tissue Mini Kit (Qiagen), with additional DNAse treatment (Qiagen). RNA quality
and quantity were assessed by spectrophotometric measurements (Nanodrop 1000,
NanoDrop Technologies, USA). For cDNA synthesis, total RNA was reversed tran-
scribed using random hexamers (Applied Biosystems, Sundbyberg, Sweden), and
Superscript III reverse transcriptase (Invitrogen Life Technologies, Paisley, UK), ac-
cording to the manufacturer’s description. Recombinant RNaseout Ribonuclease
Inhibitor (Invitrogen) was added to prevent RNase-mediated degradation. All the
cDNA-reactions were run in triplicate and the triplicates were pooled for the RT-
PCR.
Real-time RT PCR was performed using TaqMan Custom Arrays. They were
designed with TaqMan probe and primer sets for target genes and reference genes
chosen from an on-line catalog (Applied Biosystems). The sets were factory-
loaded into the 384 wells of TaqMan Arrays. Each port on the TaqMan Arrays
was loaded with cDNA corresponding to 100 ng total RNA, combined with
nuclease free water and 50 ml TaqMan Gene Expression Master Mix (Applied
Biosystems) to a ﬁnal volume of 100 ml. The TaqMan Arrays were analyzed using
the 7900HT system with a TaqMan Array Upgrade (Applied Biosystems). Thermal
cycling conditions were: 50 C for 2 min, 94.5 C for 10 min, followed by 40 cycles
of 97 C for 30 s and 59.7 C for 1 min. A combination of b-actin and cyclophilin A
were used as reference genes. Gene expression values were calculated based on
the DDCt method (Livak and Schmittgen, 2001). Brieﬂy, DCt represents the
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represents the DCt of the target group minus that of the calibrator group. Relative
quantities (RQ) were determined using the equation; RQ ¼ 2DDCt . For the cali-
brator, the equation is RQ ¼ 20, which is 1; therefore, the values for the target
group are expressed relative to this. Target and reference genes and assay id’s are
given in Table 1.
2.5. Statistics
To analyze the effect of acute ghrelin treatment or GHS-R1A knock-out on the
tissue concentration of serotonin and 5-HIAA, Student’s t-test, or ManneWhitney U
test when the variances were not equal, was used. In order to analyze the effect of
acute central ghrelin treatment, or GHS-R1A knock-out, on gene expression, Stu-
dent’s t-test was used. P-values and SEM were calculated using the DCt- values.
Differences were considered signiﬁcant at p < 0.05.3. Results
3.1. Tissue concentrations of serotonin and 5-HIAA in the amygdala
and the dorsal raphe
Acute central ghrelin administration signiﬁcantly increased the
concentration of 5-HIAA, the metabolite of serotonin, in the
amygdala (p ¼ 0.029, Fig. 1A). No signiﬁcant difference in the 5-
HIAA concentration in the amygdala was observed between the
GHS-R1A knock-out and wild-type mice (p ¼ 0.146, Fig. 1B). No
signiﬁcant changes in 5-HIAA concentrations were detected in the
dorsal raphe nucleus after acute ghrelin treatment (mean  SEM:
saline: 4046  850 fmol/mg, n ¼ 8, ghrelin: 2887  146 fmol/mg,
n ¼ 8, p ¼ 0.442 using ManneWhitney U test) or in the GHS-R1A
knock-out mice (mean  SEM: wt 2727  254 fmol/mg, n ¼ 8,
GHS-R1A knock-out 3124  215 fmol/mg, n ¼ 11, p ¼ 0.248 using
Student’s t-test).
The serotonin concentrations were not signiﬁcantly different
between the ghrelin- and saline-treated mice in either the amyg-
dala (mean  SEM: saline: 5484  212 fmol/mg, n ¼ 8; ghrelin:
5810  175 fmol/mg, n ¼ 8; p ¼ 0.255 using Student’s t-test) or the
dorsal raphe (saline: 9956  2152 fmol/mg, n ¼ 8; ghrelin:
6796  381 fmol/mg, n ¼ 8; p ¼ 0.329 using ManneWhitney UTable 1
Genes investigated in the amygdala and the dorsal raphe.
Gene name Assay ID
Receptors
5-Hydroxytryptamine receptor 1A Htr1a Mm00434106_s1
5-Hydroxytryptamine receptor 1B Htr1b Mm00439377_s1
5-Hydroxytryptamine receptor 1D Htr1d Mm00434115_s1
5-Hydroxytryptamine receptor 1F Htr1f Mm00434122_m1
5-Hydroxytryptamine receptor 2A Htr2a Mm00555764_m1
5-Hydroxytryptamine receptor 2B Htr2b Mm00434123_m1
5-Hydroxytryptamine receptor 2C Htr2c Mm00434127_m1
5-Hydroxytryptamine receptor 3A Htr3a Mm00442874_m1
5-Hydroxytryptamine receptor 3B Htr3b Mm00517424_m1
5-Hydroxytryptamine receptor 4 Htr4 Mm00434129_m1
5-Hydroxytryptamine receptor 5A Htr5a Mm00434132_m1
5-Hydroxytryptamine receptor 5B Htr5b Mm00439389_m1
5-Hydroxytryptamine receptor 6 Htr6 Mm00445320_m1
5-Hydroxytryptamine receptor 7 Htr7 Mm00434133_m1
Enzymes and transporters
Monoamine oxidase A Maoa Mm00558004_m1
Monoamine oxidase B Maob Mm00555412_m1
Serotonin transporter Slc6a4 Mm00439391_m1
Vesicular monoamine transporter 2 Slc18a2 Mm00553058_m1
Tryptophan hydroxylase 1 Tph1 Mm00493794_m1
Tryptophan hydroxylase 2 Tph2 Mm00557715_m1
Reference genes
Beta-actin Actb Mm00607939_s1
Cyclophilin A Ppia Mm03302254_g1test). Likewise, the serotonin concentrations did not differ between
the GHS-R1A knock-out and wild-type mice in either the amygdala
(mean  SEM: wt 4414  157 fmol/mg, n ¼ 9; GHS-R1A knock-out
4379 203 fmol/mg, n¼ 11; p¼ 0.899 using Student’s t-test) or the
dorsal raphe (wt 4423  450 fmol/mg, n ¼ 8; GHS-R1A knock-out
5043  457 fmol/mg, n ¼ 11; p ¼ 0.361 using Student’s t-test).
3.2. Gene expression of serotonergic receptors
In the amygdala, serotonin receptor 1a (Htr1a, RQ ¼ 1.40,
p ¼ 0.026), 2c (Htr2c, RQ ¼ 1.27, p ¼ 0.021), 5a (Htr5a, RQ ¼ 1.57,
p¼ 0.011) and 7 (Htr7, RQ¼ 1.51, p¼ 0.006) had an increasedmRNA
expression after acute ghrelin treatment relative to saline-treated
controls (Fig. 2A). The GHS-R1A knock-out mice had a decreased
mRNA expression of serotonin receptor 2c (Htr2c, RQ ¼ 0.80,
p ¼ 0.017), 5a (Htr5a, RQ ¼ 0.85, p ¼ 0.024) and 7 (Htr7, RQ ¼ 0.84,
p ¼ 0.046) compared to wild-type littermates (Fig. 2B).
In the dorsal raphe, serotonin receptor 1a (Htr1a, RQ ¼ 2.04,
p ¼ 0.013), 1b (Htr1b, RQ ¼ 1.42, p ¼ 0.024), 1d (Htr1d, RQ ¼ 1.83,
p ¼ 0.046), 1f (Htr1f, RQ ¼ 1.40, p ¼ 0.033), 2c (Htr2c, RQ ¼ 1.60,
p ¼ 0.016), 4 (Htr4, RQ ¼ 1.63, p ¼ 0.012), 6 (Htr6, RQ ¼ 1.57,
p ¼ 0.008) and 7 (Htr7, RQ ¼ 1.56, p ¼ 0.010) had an increased
mRNA expression after acute ghrelin treatment relative to saline-
treated controls (Fig. 2C). The GHS-R1A knock-out mice had a
decreased mRNA expression of serotonin receptor 2c (Htr2c,
RQ ¼ 0.86, p ¼ 0.025) and 3a (Htr3a, RQ ¼ 0.61, p ¼ 0.021)
compared to wild-type littermates (Fig. 2D). Serotonin receptor 2b
(Htr2b) and 3b (Htr3b) mRNAs were not expressed in any of the
tissues studied.
3.3. Gene expression of serotonergic enzymes and transporters
In the amygdala, the mRNA expression of monoamine oxidase A
(Maoa) and monoamine oxidase B (Maob) was not changed in the
ghrelin-treated mice relative to saline-treated controls (Maoa,
RQ ¼ 1.05, p ¼ 0.582; Maob, RQ ¼ 0.91, p ¼ 0.268). The GHS-R1A
knock-out mice had a decreased mRNA expression of monoamine
oxidase A (Maoa) compared to wild-type littermates (RQ ¼ 0.85,
p ¼ 0.026) (Fig. 3B), while the mRNA expression of monoamine
oxidase B (Maob) was not changed (RQ ¼ 0.90, p ¼ 0.111). Trypto-
phan hydroxylase 1 (Tph1), tryptophan hydroxylase 2 (Tph2) the
serotonin transporter (Slc6a4), and the vesicular monoamine
transporter 2 (Slc18a2) mRNAs were not expressed in the
amygdala.
In the dorsal raphe, monoamine oxidase A (Maoa), tryptophan
hydroxylase 2 (Tph2), the serotonin transporter (Slc6a4), and the
vesicular monoamine transporter 2 (Slc18a2) did not display a
signiﬁcantly altered mRNA expression in the ghrelin-treated mice
relative to saline-treated controls (Maoa, RQ ¼ 1.16, p ¼ 0.297;
Tph2, RQ ¼ 3.68, p ¼ 0.181; Slc6a4, RQ ¼ 4.81, p ¼ 0.149; Slc18a2,
RQ ¼ 1.25, p ¼ 0.564) or in GHS-R1A knock-out mice relative to
wild-type controls (Maoa, RQ ¼ 0.98, p ¼ 0.821; Tph2, RQ ¼ 0.65,
p ¼ 0.629; Slc6a4, RQ ¼ 0.48, p ¼ 0.474; Slc18a2, RQ ¼ 0.48,
p ¼ 0.299). The mRNA expression of monoamine oxidase B (Maob)
was increased in the dorsal raphe after ghrelin treatment
(RQ ¼ 1.48, p ¼ 0.042) (Fig. 3C), while it was not changed in the
GHS-R1A knock-out mice (RQ ¼ 0.98, p ¼ 0.879). Tryptophan hy-
droxylase 1 (Tph1) mRNA was not expressed in the dorsal raphe.
3.4. Comparison of the mRNA expression of GHS-R1A in the
amygdala, dorsal raphe and hypothalamus
The mRNA expression of GHS-R1A was 3.69 fold higher in the
dorsal raphe and 13.85 fold higher in the hypothalamus than in the
amygdala (Fig. 4).
Fig. 1. Tissue concentrations of 5-hydroxyindoleacetic acid (5-HIAA) in the amygdala of (A) mice treated i.c.v. with ghrelin or saline vehicle and (B) GHS-R1A knock-out and wild-
type mice. Values are expressed as fmol/mg dissected brain tissue. *p < 0.05, Student’s t-test.
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The results of the present study support the hypothesis that
ghrelin targets the central serotonergic system. Our studies
focused on two brain areas, the amygdala and the dorsal raphe. In
the amygdala, acute central ghrelin administration increased
serotonergic turnover (reﬂected by increased concentration of the
serotonin metabolite 5-HIAA) and also increased the mRNA
expression of a number of serotonergic receptors. Acute central
ghrelin treatment also appeared to inﬂuence serotonergic
signaling in the dorsal raphe, reﬂected by an increased mRNAFig. 2. mRNA expression of serotonergic receptors in the amygdala of (A) ghrelin- and salin
dorsal raphe of (C) ghrelin- and saline-treated mice and (D) GHS-R1A knock-out and wild-
wild-type controls. Amygdala: n ¼ 10 per group. Dorsal raphe: n ¼ 10 in the saline-treated gr
and **p < 0.01 compared to vehicle, Student’s t-test.expression of serotonergic receptors in this region. Consistent
with these data, GHS-R1A knock-out mice, that lack ghrelin
signaling via GHS-R1A, display reduced mRNA expression of a
number of genes linked to serotonergic signaling, including
several serotonergic receptors (in the amygdala and dorsal raphe)
and also monoamine oxidase A (an enzyme involved in the
breakdown of serotonin) in the amygdala. Given that central se-
rotonin pathways are linked to mood and the expression of anx-
iety behavior, our new data suggest that serotonergic pathways
provide one possible neurochemical substrate underpinning
ghrelin’s effects on anxiety-like behavior.e-treated mice and (B) GHS-R1A knock-out and wild-type littermate mice and in the
type littermate mice. Values are expressed as mean (þSEM) relative to saline-treated/
oup, n ¼ 9 in the ghrelin-treated group. GHS-R1A knock-out: n ¼ 8 per group. *p < 0.05
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Fig. 3. mRNA expression of monoamine oxidase A (Maoa) and monoamine oxidase B (Maob) in the amygdala of (A) ghrelin- and saline-treated mice and (B) GHS-R1A knock-out
and wild-type littermate mice and in the dorsal raphe of (C) ghrelin- and saline-treated mice and (D) GHS-R1A knock-out and wild-type littermate mice. Values are expressed as
mean (þSEM) relative to saline-treated/wild-type controls. Amygdala: n ¼ 10 per group. Dorsal raphe: n ¼ 10 in the saline-treated group, n ¼ 9 in the ghrelin-treated group. GHS-
R1A knock-out: n ¼ 8 per group. *p < 0.05 compared to vehicle, Student’s t-test.
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amygdala
To explore the effects of ghrelin on the activity of the seroto-
nergic neurons, we measured the tissue concentrations of seroto-
nin and its metabolite 5-HIAA after acute ghrelin treatment and in
GHS-R1A knock-out mice in the amygdala and the dorsal raphe.
Whereas an increased tissue concentration of the serotonin
metabolite, 5-HIAA, would be indicative of an increased activity of
the serotonergic neurons, an increased tissue concentration of se-
rotoninwould suggest an increased serotonergic innervation of the
tissue. In our study the concentration of 5-HIAA was increased in
the amygdala in the ghrelin-treated group, which could suggest an
increased activity of the serotonergic neurons projecting to this
area after acute ghrelin treatment. The GHS-R1A knock-out mice
displayed a tendency towards decreased concentration of 5-HIAA,
consistent with a previous report (Patterson et al., 2010). TheseFig. 4. mRNA expression of GHS-R1A in the amygdala (Amy) compared to the dorsal
raphe (DR) and the hypothalamus (Hyp). Values are expressed as mean (þSEM) rela-
tive to amygdala. Amygdala: n ¼ 10, dorsal raphe: n ¼ 10, hypothalamus: n ¼ 10.authors also reported a signiﬁcant increase in 5-HIAA concentra-
tion in the amygdala after 2 weeks exposure to a chronic unpre-
dictable stress. Interestingly, these mice had signiﬁcantly elevated
plasma ghrelin levels, in line with our ﬁnding that ghrelin increases
the tissue concentration of 5-HIAA in the amygdala.
The increased serotonergic activity in the amygdala may be
implicated in the anxiogenic effect of ghrelin. Clinical studies have
shown that individuals carrying the short variant of a poly-
morphism in the serotonin transporter gene have reduced tran-
scription of the serotonin transporter, resulting in reduced
serotonin reuptake, and presumably increased serotonin levels in
the synaptic cleft. Interestingly, they also have higher scores on
anxiety-related personality traits (Lesch et al., 1996), and increased
amygdala activation in response to fearful stimuli (Hariri et al.,
2002). These clinical ﬁndings are supported by animal studies
showing that mice with genetic knock-out of the serotonin trans-
porter have increased extracellular serotonin levels and increased
anxiety-like behavior, while overexpression of the serotonin
transporter gene results in decreased anxiety-like behavior
(Holmes, 2008).
We also explored the tissue concentrations of serotonin and
found that they were unaltered by acute ghrelin treatment in the
amygdala as well as in the dorsal raphe. We did not expect acute
ghrelin treatment to alter serotonin concentration as this would be
indicative of a change in serotonin innervation in these areas.
However, serotonin concentration was not altered in the GHS-R1A
knockout mice either, suggesting that chronic (life-long) changes in
ghrelin signaling do not alter serotonin innervation.
4.2. The effect of ghrelin signaling on the mRNA expression of
serotonin-related genes
Further evidence supporting our hypothesis that the central
serotonin system is a target for ghrelin is provided by our studies
C. Hansson et al. / Neuropharmacology 79 (2014) 498e505 503exploring the mRNA expression of serotonergic receptors in the
dorsal raphe and the amygdala, many of which showed increased
expression following acute ghrelin treatment and conversely,
showed reduced expression in GHS-R1A knock-out mice. The
mRNA expression of monoamine oxidase A was also found to be
decreased in the amygdala of the GHS-R1A knock-out mice
compared to wild-type controls.
We found that serotonin receptor 2c, 5a and 7 showed signiﬁ-
cantly increased mRNA expression in the amygdala after acute
ghrelin treatment but had signiﬁcantly decreased mRNA expres-
sion in the amygdala of GHS-R1A knock-out mice. The serotonin
receptor 2c is involved in the regulation of food intake as well as in
mood (Serretti et al., 2004) and activation of this receptor in the
amygdala has been proposed to be associated with fear responses
(Drago and Serretti, 2009). Genetic knock-out studies show that
this receptor is important for the regulation of anxiety-like
behavior and Htr2c knock-out mice display a less anxious pheno-
type than wild-type controls (Heisler et al., 2007). Notably, this
receptor had an increasedmRNA expression after ghrelin treatment
and a decreased mRNA expression in the GHS-R1A knock-out mice
in both of the studied regions. The serotonin receptor 5a has not
been extensively studied due to lack of speciﬁc ligands for the re-
ceptor. Interestingly, the receptors that have similar binding afﬁn-
ities as the 5a receptor are serotonin receptor 1a and 7 (Thomas,
2006), which also displayed an increased expression in the amyg-
dala in our study. Regarding brain function, the serotonin receptor
5a might be involved in exploratory behavior, as serotonin receptor
5a knock-out mice have increased exploratory behavior (Grailhe
et al., 1999).
The serotonin receptor 1a had an increased mRNA expression in
the amygdala and the dorsal raphe after acute ghrelin administra-
tion in our study. In the amygdala, the serotonin receptor 1a is a
postsynaptic receptor, while in the dorsal raphe, it functions as a
somatodendritic autoreceptor, decreasing serotonin release
(Barnes and Sharp, 1999). It is interesting to note that activation of
presynaptic (autoreceptors) and postsynaptic 5-HT1A receptors
have opposing effects in the regulation of anxiety. While adminis-
tration of 5-HT1A agonists in the amygdala has anxiogenic effects,
administration of a 5-HT1A agonist into the dorsal raphe is anxio-
lytic (Akimova et al., 2009).
In the dorsal raphe, we also observed an increased mRNA
expression of serotonin receptor 1b,1d and 1f in the ghrelin-treated
animals. Serotonin receptor 1b and 1d are also autoreceptors, but in
contrast to serotonin receptor 1a these are presynaptically located
in the serotonergic nerve terminals (Barnes and Sharp, 1999). We
also observed an increased mRNA expression of serotonin receptor
4, 6, and 7 in the dorsal raphe after ghrelin treatment, all of which
are coupled to Gs proteins, stimulating adenylate cyclase (Hoyer
et al., 2002). Serotonin receptor 4 agonists have previously been
reported to increase the ﬁring rate of serotonin neurons in the
dorsal raphe (Lucas and Debonnel, 2002). Moreover, serotonergic
neurons in the dorsal raphe of Htr4 knock-out mice display reduced
spontaneous electrical activity compared to wild-type mice
(Conductier et al., 2006). These data indicate that 5-HT4 receptors
are important for the regulation of serotonergic activity. Regarding
the functional signiﬁcance of 5-HT6, there are indications that this
receptor is involved in the regulation of anxiety as Htr6 knock-out
mice display increased anxiety-like behavior (Barnes and Sharp,
1999). Acute stress has been shown to increase the mRNA expres-
sion of Htr7 in the hippocampus (Yau et al., 2001).
In the dorsal raphe we found a decreased mRNA expression of
Htr3a in the GHS-R1A knock-out mice. Htr3a has also been impli-
cated in anxiety. Knock-out of the Htr3a gene in mice is anxiolytic
(Kelley et al., 2003). Moreover, a polymorphism in the Htr3a gene is
associated with the personality trait harm avoidance in women(Melke et al., 2003). This polymorphism also modulates amygdala
activation (Iidaka et al., 2005) and affects the protein levels of Htr3a
(Niesler et al., 2001).
Monoamine oxidase, the enzyme responsible for metabolizing
biogenic amines, exists in two forms, A and B. Monoamine oxidase
A preferentially metabolizes serotonin and noradrenaline, while
monoamine oxidase B preferentially metabolizes benzylamine and
phenylethylamine. Dopamine is metabolized by both enzymes.
Some studies suggest that serotonin can also be metabolized by
monoamine oxidase B, although at a slower rate (Mitra and Guha,
1980). Monoamine oxidase A, the main enzyme responsible for
metabolizing serotonin, had a decreased mRNA expression in the
amygdala in the GHS-R1A knock-out mice. The decreased mRNA
expression is in line with the trend towards decreased 5-HIAA
concentrations in the amygdala in the GHS-R1A knock-out mice.
Monoamine oxidase B is expressed in serotonergic neurons, glia
cells and astrocytes. We found an increased mRNA expression of
Maob in the dorsal raphe after acute ghrelin treatment. The
increased mRNA expression may be indicative of an increased
transcriptional activity of serotonergic neurons in the dorsal raphe
after acute ghrelin treatment. Asmonoamine oxidase Bmetabolizes
dopamine, it could possibly reﬂect increased dopamine in the
dorsal raphe, although further studies would be needed to conﬁrm
this. The dorsal raphe is innervated by dopamine neurons origi-
nating in the ventral tegmental area (Kalen et al., 1988), and
dopamine cells in this region are known to express GHS-R1A and be
ghrelin responsive (Abizaid et al., 2006). Accordingly, stimulation of
GHS-R1A in the ventral tegmental area may increase dopamine
release in the dorsal raphe, an area where dopamine has been
shown to activate serotonergic neurons via dopaminergic D2 re-
ceptors (Ferre and Artigas, 1993).
4.3. The amygdala as a direct or indirect target for ghrelin
To our knowledge, this is the ﬁrst study quantifying the
expression of GHS-R1A mRNA in the amygdala of mice and
comparing it to the mRNA expression levels in other brain areas
known to express GHS-R1A. Consistent with these results, we have
previously identiﬁed the presence of GHS-R1A in the amygdala of
rats using in situ hybridization (Alvarez-Crespo et al., 2012).
Notably, the mRNA expression level of GHS-R1A in the amygdala
was considerably lower than that observed in the dorsal raphe and
the hypothalamus. Further studies, using site-speciﬁc injections,
would be required to determine the extent to which ghrelin exerts
direct or indirect effects on the serotonergic system in these areas.
In our study, ghrelin was administered i.c.v. and the effects that we
observe could be either a direct effect, via binding to GHS-R1A in
the amygdala, or may involve indirect activation of afferent pro-
jections. Evidence supporting the amygdala as a direct paren-
chymal target for ghrelin is suggested by studies showing that site-
speciﬁc administration of ghrelin into the amygdala increases
anxiety-like behavior (Carlini et al., 2004). Moreover, electrophys-
iological studies have found ghrelin-responsive neurons in the
basolateral amygdala (Toth et al., 2009). It is also possible that
ghrelin increases the activity of serotonergic cells projecting to the
amygdala by acting on the serotonergic cell bodies in the dorsal
raphe. There are direct serotonergic pathways from the dorsal
raphe to the amygdala (Wang and Aghajanian, 1977) and we have
previously shown that ghrelin affects the ﬁring rate of cells in the
dorsal raphe, using extracellular recordings on brain slice prepa-
rations (Hansson et al., 2011). It should be noted however, that
another study reported that ghrelin depolarizes putative seroto-
nergic dorsal raphe cells, using whole-cell patch clamp recordings
(Ogaya et al., 2011). As ghrelin seems to have an inhibitory effect on
serotonin release in the hypothalamus (Brunetti et al., 2002), it
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release also in the amygdala. There are indications, however, that
dorsal raphe cells exert different effects in the hypothalamus and
the amygdala, evidenced e.g. by the inhibitory effect of serotonergic
dorsal raphe cells on the amygdala (Wang and Aghajanian, 1977),
while the effect of serotonergic dorsal raphe cells is excitatory in
the paraventricular nucleus (PVN) of the hypothalamus (Saphier
and Feldman, 1989). The differential regulation of hypothalamus
and amygdala could be due to different neurons projecting to these
different target areas from the dorsal raphe. Although a minor part
of the dorsal raphe cells provide branching collaterals to the central
nucleus of the amygdala and to the PVN, the majority of the sero-
tonergic cells do not branch to both of these areas, but project to
either the amygdala or the hypothalamus (Petrov et al., 1994) and it
is different nerve ﬁbers projecting from the dorsal raphe that
innervate the amygdala than the hypothalamus (Moore et al., 1978).
The effects of ghrelin could also be mediated via other ghrelin-
responsive brain areas that project to the amygdala. GHS-R1A is
expressed in the external lateral parabrachial nucleus (PBN)
(Zigman et al., 2006) and this subnucleus of the PBN sends neuronal
projections to the amygdala (Tokita et al., 2010). GHS-R1A is also
densely expressed in the hypothalamus (Zigman et al., 2006) and
there are neuronal projections from the PVN to the amygdala
(Sofroniew, 1980), suggesting that ghrelin responsive neurons
could project to the amygdala, thereby affecting the release of se-
rotonin by acting on presynaptic terminals, or affect gene expres-
sion by acting on cells in the amygdala.4.4. Concluding remarks
The results of the present study suggest neurochemical
convergence of ghrelin-responsive circuits with central seroto-
nergic pathways. In particular we show that serotonin metabolism
and patterns of mRNA expression of serotonin receptor subtypes in
the dorsal raphe and amygdala are affected by acute central de-
livery of ghrelin and also by knock-out of the ghrelin receptor, GHS-
R1A. In future studies, it will be interesting to determine the con-
sequences and time course of the effects of central ghrelin action on
protein levels of serotonin-linked genes in relevant brain areas. It
will also be of importance to determine the extent to which the
central serotonin system mediates the effects of ghrelin on
behavioral endpoints including those linked to mood. Given the
established role of central serotonergic systems in mood, together
with the emerging data implicating central ghrelin signaling
pathways at the interface between feeding control and the regu-
lation of anxiety-like behaviors, the central serotonin system
emerges as a novel candidate that could mediate ghrelin’s effects
on anxiety-like behavior.Acknowledgments
This work was primarily supported by NeuroFAST (FP7-KBBE-
2009-3-245009 to S.L.D.) but also by additional European Com-
mission Seventh Framework grants (FP7-KBBE-2010-4-266408,
Full4Health and FP7-HEALTH-2009-241592, EurOCHIP; both to
S.L.D.), the Swedish Research Council for Medicine (2010-12208 to
HN, 2011-3054 to KPS and 2012-1758 to SLD), Forskning och
Utvecklingsarbete/Avtal om Läkarutbildning och Forskning Göte-
borg (ALFGBG-138741 to S.L.D.), the Swedish Foundation for Stra-
tegic Research to Sahlgrenska Center for Cardiovascular and
Metabolic Research (A305e188), and NovoNordisk Fonden (to
S.L.D.). The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript. We
also thank the Genomics Core Facility platform at the SahlgrenskaAcademy, University of Gothenburg, which was funded by a grant
from the Knut and Alice Wallenberg Foundation.
Abbreviations
5-HIAA 5-hydroxyindoleacetic acid
5-HT serotonin
GHS-R1Agrowth hormone secretagogue receptor 1A
Htr1a serotonin receptor 1A
Htr1b serotonin receptor 1B
Htr1d serotonin receptor 1D
Htr1f serotonin receptor 1F
Htr2a serotonin receptor 2A
Htr2c serotonin receptor 2C
Htr3a serotonin receptor 3A
Htr4 serotonin receptor 4
Htr5a serotonin receptor 5A
Htr5b serotonin receptor 5B
Htr6 serotonin receptor 6
Htr7 serotonin receptor 7
i.c.v. intracerebroventricular
Maoa monoamine oxidase A
Maob monoamine oxidase B
PBN parabrachial nucleus
PVN paraventricular nucleus
RQ relative quantiﬁcation
Slc6a4 serotonin transporter
Slc18a2 vesicular monoamine transporter 2
SSRI selective serotonin reuptake inhibitor
Tph1 tryptophan hydroxylase 1
Tph2 tryptophan hydroxylase 2
References
Abizaid, A., Liu, Z.W., Andrews, Z.B., Shanabrough, M., Borok, E., Elsworth, J.D.,
Roth, R.H., Sleeman, M.W., Picciotto, M.R., Tschop, M.H., Gao, X.B., Horvath, T.L.,
2006. Ghrelin modulates the activity and synaptic input organization of
midbrain dopamine neurons while promoting appetite. J. Clin. Investig. 116,
3229e3239.
Akimova, E., Lanzenberger, R., Kasper, S., 2009. The serotonin-1A receptor in anxiety
disorders. Biol. Psychiatry 66, 627e635.
Alvarez-Crespo, M., Skibicka, K.P., Farkas, I., Molnar, C.S., Egecioglu, E.,
Hrabovszky, E., Liposits, Z., Dickson, S.L., 2012. The amygdala as a neurobio-
logical target for ghrelin in rats: neuroanatomical, electrophysiological and
behavioral evidence. PloS One 7, e46321.
Asakawa, A., Inui, A., Kaga, T., Yuzuriha, H., Nagata, T., Fujimiya, M., Katsuura, G.,
Makino, S., Fujino, M.A., Kasuga, M., 2001. A role of ghrelin in neuroendocrine
and behavioral responses to stress in mice. Neuroendocrinology 74, 143e147.
Barnes, N.M., Sharp, T., 1999. A review of central 5-HT receptors and their function.
Neuropharmacology 38, 1083e1152.
Brunetti, L., Recinella, L., Orlando, G., Michelotto, B., Di Nisio, C., Vacca, M., 2002.
Effects of ghrelin and amylin on dopamine, norepinephrine and serotonin
release in the hypothalamus. Eur. J. Pharmacol. 454, 189e192.
Carlini, V.P., Gaydou, R.C., Schioth, H.B., de Barioglio, S.R., 2007. Selective serotonin
reuptake inhibitor (ﬂuoxetine) decreases the effects of ghrelin on memory
retention and food intake. Regul. Pept. 140, 65e73.
Carlini, V.P., Monzon, M.E., Varas, M.M., Cragnolini, A.B., Schioth, H.B.,
Scimonelli, T.N., de Barioglio, S.R., 2002. Ghrelin increases anxiety-like behavior
and memory retention in rats. Biochem. Biophys. Res. Commun. 299, 739e743.
Carlini, V.P., Varas, M.M., Cragnolini, A.B., Schioth, H.B., Scimonelli, T.N., de
Barioglio, S.R., 2004. Differential role of the hippocampus, amygdala, and dorsal
raphe nucleus in regulating feeding, memory, and anxiety-like behavioral re-
sponses to ghrelin. Biochem. Biophys. Res. Commun. 313, 635e641.
Conductier, G., Dusticier, N., Lucas, G., Cote, F., Debonnel, G., Daszuta, A., Dumuis, A.,
Nieoullon, A., Hen, R., Bockaert, J., Compan, V., 2006. Adaptive changes in se-
rotonin neurons of the raphe nuclei in 5-HT(4) receptor knock-out mouse. Eur. J.
Neurosci. 24, 1053e1062.
Costall, B., Kelly, M.E., Naylor, R.J., Onaivi, E.S., Tyers, M.B., 1989. Neuroanatomical
sites of action of 5-HT3 receptor agonist and antagonists for alteration of
aversive behaviour in the mouse. Br. J. Pharmacol. 96, 325e332.
Currie, P.J., John, C.S., Nicholson, M.L., Chapman, C.D., Loera, K.E., 2010. Hypotha-
lamic paraventricular 5-hydroxytryptamine inhibits the effects of ghrelin on
eating and energy substrate utilization. Pharmacol. Biochem. Behav. 97, 152e
155.
C. Hansson et al. / Neuropharmacology 79 (2014) 498e505 505Dahlstroem, A., Fuxe, K., 1964. Evidence for the existence of monoamine-containing
neurons in the central nervous system. I. demonstration of monoamines in the
cell bodies of brain stem neurons. Acta Physiol. Scand. Suppl. 232, 231e255.
Davis, M., 1992. The role of the amygdala in fear and anxiety. Annu. Rev. Neurosci.
15, 353e375.
Diano, S., Farr, S.A., Benoit, S.C., McNay, E.C., da Silva, I., Horvath, B., Gaskin, F.S.,
Nonaka, N., Jaeger, L.B., Banks, W.A., Morley, J.E., Pinto, S., Sherwin, R.S., Xu, L.,
Yamada, K.A., Sleeman, M.W., Tschop, M.H., Horvath, T.L., 2006. Ghrelin controls
hippocampal spine synapse density and memory performance. Nat. Neurosci. 9,
381e388.
Drago, A., Serretti, A., 2009. Focus on HTR2C: a possible suggestion for genetic
studies of complex disorders. Am. J. Med. Genet. B Neuropsychiatr. Genet. 150B,
601e637.
Egecioglu, E., Jerlhag, E., Salome, N., Skibicka, K.P., Haage, D., Bohlooly, Y.M.,
Andersson, D., Bjursell, M., Perrissoud, D., Engel, J.A., Dickson, S.L., 2010. Ghrelin
increases intake of rewarding food in rodents. Addict. Biol. 15, 304e311.
Ferre, S., Artigas, F., 1993. Dopamine D2 receptor-mediated regulation of serotonin
extracellular concentration in the dorsal raphe nucleus of freely moving rats.
J. Neurochem. 61, 772e775.
Ghersi, M.S., Casas, S.M., Escudero, C., Carlini, V.P., Buteler, F., Cabrera, R.J.,
Schioth, H.B., de Barioglio, S.R., 2011. Ghrelin inhibited serotonin release from
hippocampal slices. Peptides 32, 2367e2371.
Graeff, F.G., Guimaraes, F.S., De Andrade, T.G., Deakin, J.F., 1996. Role of 5-HT in
stress, anxiety, and depression. Pharmacol. Biochem. Behav. 54, 129e141.
Grailhe, R., Waeber, C., Dulawa, S.C., Hornung, J.P., Zhuang, X., Brunner, D.,
Geyer, M.A., Hen, R., 1999. Increased exploratory activity and altered response to
LSD in mice lacking the 5-HT(5A) receptor. Neuron 22, 581e591.
Hansson, C., Annerbrink, K., Nilsson, S., Bah, J., Olsson, M., Allgulander, C.,
Andersch, S., Sjodin, I., Eriksson, E., Dickson, S.L., 2013. A possible association
between panic disorder and a polymorphism in the preproghrelingene. Psy-
chiatry Res. 206, 22e25.
Hansson, C., Haage, D., Taube, M., Egecioglu, E., Salome, N., Dickson, S.L., 2011. Central
administration of ghrelin alters emotional responses in rats: behavioural, elec-
trophysiological and molecular evidence. Neuroscience 180, 201e211.
Hariri, A.R., Mattay, V.S., Tessitore, A., Kolachana, B., Fera, F., Goldman, D., Egan, M.F.,
Weinberger, D.R., 2002. Serotonin transporter genetic variation and the
response of the human amygdala. Science 297, 400e403.
Heisler, L.K., Zhou, L., Bajwa, P., Hsu, J., Tecott, L.H., 2007. Serotonin 5-HT(2C) re-
ceptors regulate anxiety-like behavior. Genes Brain Behav. 6, 491e496.
Holmes, A., 2008. Genetic variation in cortico-amygdala serotonin function and risk
for stress-related disease. Neurosci. Biobehav. Rev. 32, 1293e1314.
Hoyer, D., Hannon, J.P., Martin, G.R., 2002. Molecular, pharmacological and func-
tional diversity of 5-HT receptors. Pharmacol. Biochem. Behav. 71, 533e554.
Iidaka, T., Ozaki, N., Matsumoto, A., Nogawa, J., Kinoshita, Y., Suzuki, T., Iwata, N.,
Yamamoto, Y., Okada, T., Sadato, N., 2005. A variant C178T in the regulatory
region of the serotonin receptor gene HTR3A modulates neural activation in the
human amygdala. J. Neurosci. 25, 6460e6466.
Jaszberenyi, M., Bujdoso, E., Bagosi, Z., Telegdy, G., 2006. Mediation of the behav-
ioral, endocrine and thermoregulatory actions of ghrelin. Horm. Behav. 50,
266e273.
Jerlhag, E., Egecioglu, E., Dickson, S.L., Andersson, M., Svensson, L., Engel, J.A., 2006.
Ghrelin stimulates locomotor activity and accumbal dopamine-overﬂow via
central cholinergic systems in mice: implications for its involvement in brain
reward. Addict. Biol. 11, 45e54.
Jerlhag, E., Egecioglu, E., Landgren, S., Salome, N., Heilig, M., Moechars, D., Datta, R.,
Perrissoud, D., Dickson, S.L., Engel, J.A., 2009. Requirement of central ghrelin
signaling for alcohol reward. Proc. Natl. Acad. Sci. U. S. A. 106, 11318e11323.
Kalen, P., Skagerberg, G., Lindvall, O., 1988. Projections from the ventral tegmental
area and mesencephalic raphe to the dorsal raphe nucleus in the rat. Evidence
for a minor dopaminergic component. Exp. Brain Res. 73, 69e77.
Kanehisa, M., Akiyoshi, J., Kitaichi, T., Matsushita, H., Tanaka, E., Kodama, K.,
Hanada, H., Isogawa, K., 2006. Administration of antisense DNA for ghrelin
causes an antidepressant and anxiolytic response in rats. Prog. Neuro-
psychopharmacol. Biol. Psychiatry 30, 1403e1407.
Kelley, S.P., Bratt, A.M., Hodge, C.W., 2003. Targeted gene deletion of the 5-HT3A
receptor subunit produces an anxiolytic phenotype in mice. Eur. J. Pharmacol.
461, 19e25.
Kojima, M., Hosoda, H., Date, Y., Nakazato, M., Matsuo, H., Kangawa, K., 1999.
Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature
402, 656e660.
Lesch, K.P., Bengel, D., Heils, A., Sabol, S.Z., Greenberg, B.D., Petri, S., Benjamin, J.,
Muller, C.R., Hamer, D.H., Murphy, D.L., 1996. Association of anxiety-related
traits with a polymorphism in the serotonin transporter gene regulatory re-
gion. Science 274, 1527e1531.Livak, K.J., Schmittgen, T.D., 2001. Analysis of relative gene expression data using
real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25,
402e408.
Lucas, G., Debonnel, G., 2002. 5-HT4 receptors exert a frequency-related facilitatory
control on dorsal raphe nucleus 5-HT neuronal activity. Eur. J. Neurosci. 16,
817e822.
Lutter, M., Sakata, I., Osborne-Lawrence, S., Rovinsky, S.A., Anderson, J.G., Jung, S.,
Birnbaum, S., Yanagisawa, M., Elmquist, J.K., Nestler, E.J., Zigman, J.M., 2008. The
orexigenic hormone ghrelin defends against depressive symptoms of chronic
stress. Nat. Neurosci. 11, 752e753.
Melke, J., Westberg, L., Nilsson, S., Landen, M., Soderstrom, H., Baghaei, F.,
Rosmond, R., Holm, G., Bjorntorp, P., Nilsson, L.G., Adolfsson, R., Eriksson, E.,
2003. A polymorphism in the serotonin receptor 3A (HTR3A) gene and its as-
sociation with harm avoidance in women. Arch. Gen. Psychiatry 60, 1017e1023.
Mitra, C., Guha, S.R., 1980. Serotonin oxidation by type B MAO of rat brain. Biochem.
Pharmacol. 29, 1213e1216.
Moore, R.Y., Halaris, A.E., Jones, B.E., 1978. Serotonin neurons of the midbrain raphe:
ascending projections. J. Comp. Neurol. 180, 417e438.
Niesler, B., Flohr, T., Nothen, M.M., Fischer, C., Rietschel, M., Franzek, E., Albus, M.,
Propping, P., Rappold, G.A., 2001. Association between the 5’ UTR variant C178T
of the serotonin receptor gene HTR3A and bipolar affective disorder. Pharma-
cogenetics 11, 471e475.
Ogaya, M., Kim, J., Sasaki, K., 2011. Ghrelin postsynaptically depolarizes dorsal raphe
neurons in rats in vitro. Peptides 32, 1606e1616.
Patterson, Z.R., Ducharme, R., Anisman, H., Abizaid, A., 2010. Altered metabolic and
neurochemical responses to chronic unpredictable stressors in ghrelin receptor-
deﬁcient mice. Eur. J. Neurosci. 32, 632e639.
Paxinos, G., Franklin, K., 2001. The Mouse Brain in Stereotaxic Coordinates. Aca-
demic Press/Elsevier, San Diego, California, USA.
Perello, M., Sakata, I., Birnbaum, S., Chuang, J.C., Osborne-Lawrence, S.,
Rovinsky, S.A., Woloszyn, J., Yanagisawa, M., Lutter, M., Zigman, J.M., 2010.
Ghrelin increases the rewarding value of high-fat diet in an orexin-dependent
manner. Biol. Psychiatry 67, 880e886.
Petrov, T., Krukoff, T.L., Jhamandas, J.H., 1994. Chemically deﬁned collateral pro-
jections from the pons to the central nucleus of the amygdala and hypothalamic
paraventricular nucleus in the rat. Cell Tissue Res. 277, 289e295.
Pinilla, L., Barreiro, M.L., Tena-Sempere, M., Aguilar, E., 2003. Role of ghrelin in the
control of growth hormone secretion in prepubertal rats: interactions with
excitatory amino acids. Neuroendocrinology 77, 83e90.
Salome, N., Taube, M., Egecioglu, E., Hansson, C., Stenstrom, B., Chen, D.,
Andersson, D.R., Georg Kuhn, H., Ohlsson, C., Dickson, S.L., 2011. Gastrectomy
alters emotional reactivity in rats: neurobiological mechanisms. Eur. J. Neurosci.
33, 1685e1695.
Saphier, D., Feldman, S., 1989. Paraventricular nucleus neuronal responses following
electrical stimulation of the midbrain dorsal raphe: evidence for cotrans-
mission. Exp. Brain Res. 78, 407e414.
Serretti, A., Artioli, P., De Ronchi, D., 2004. The 5-HT2C receptor as a target for mood
disorders. Expert Opin. Ther. Targets 8, 15e23.
Skibicka, K.P., Hansson, C., Egecioglu, E., Dickson, S.L., 2012. Role of ghrelin in food
reward: impact of ghrelin on sucrose self-administration and mesolimbic dopa-
mine and acetylcholine receptor gene expression. Addict. Biol. 17 (1), 95e107.
Soderpalm, B., Engel, J.A., 1990. Serotonergic involvement in conﬂict behaviour. Eur.
Neuropsychopharmacol. 1, 7e13.
Sofroniew, M.V., 1980. Projections from vasopressin, oxytocin, and neurophysin
neurons to neural targets in the rat and human. J. Histochem. Cytochem. 28,
475e478.
Thomas, D.R., 2006. 5-ht5A receptors as a therapeutic target. Pharmacol. Ther. 111,
707e714.
Tokita, K., Inoue, T., Boughter Jr., J.D., 2010. Subnuclear organization of parabrachial
efferents to the thalamus, amygdala and lateral hypothalamus in C57BL/6J mice:
a quantitative retrograde double labeling study. Neuroscience 171, 351e365.
Toth, K., Laszlo, K., Lukacs, E., Lenard, L., 2009. Intraamygdaloid microinjection of
acylated-ghrelin inﬂuences passive avoidance learning. Behav. Brain Res. 202,
308e311.
Tschop, M., Smiley, D.L., Heiman, M.L., 2000. Ghrelin induces adiposity in rodents.
Nature 407, 908e913.
Wang, R.Y., Aghajanian, G.K., 1977. Inhibition of neurons in the amygdala by dorsal
raphe stimulation: mediation through a direct serotonergic pathway. Brain Res.
120, 85e102.
Yau, J.L., Noble, J., Seckl, J.R., 2001. Acute restraint stress increases 5-HT7 receptor
mRNA expression in the rat hippocampus. Neurosci. Lett. 309, 141e144.
Zigman, J.M., Jones, J.E., Lee, C.E., Saper, C.B., Elmquist, J.K., 2006. Expression of
ghrelin receptor mRNA in the rat and the mouse brain. J. Comp. Neurol. 494,
528e548.
